VRCA

Verrica Pharmaceuticals

• NASDAQ·06/22 16:45

  Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts

• TipRanks·06/22 14:15

  H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)

• PUBT·06/22 12:05

  Verrica doses first US patient in pivotal Phase 3 COVE-3 trial of YCANTH for common warts

• Reuters·06/22 12:05

  VERRICA PHARMACEUTICALS ANNOUNCES FIRST U.S. PATIENT DOSED IN THE SECOND PIVOTAL CLINICAL TRIAL (COVE-3) OF ITS PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS

• TipRanks·06/10 16:33

  Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV

• TipRanks·06/09 20:58

  Verrica Shareholders Approve Governance Measures at Annual Meeting

• PUBT·06/09 20:06

  Verrica Pharmaceuticals shareholders approve amended 2018 equity incentive plan at annual meeting

• PUBT·05/28 12:09

  Verrica Pharma CEO Jayson Rieger to present at Jefferies Global Healthcare Conference

• Dow Jones·05/26 11:01

  Verrica Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

• Dow Jones·05/26 11:01

  Verrica Pharmaceuticals Price Target Announced at $12.00/Share by HC Wainwright & Co.

• Benzinga·05/26 10:51

  HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

• TipRanks·05/26 10:19

  Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright

• Reuters·05/26 10:14

  VERRICA PHARMACEUTICALS INC <VRCA.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $12

• Reuters·05/26 07:31

  U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy

• PUBT·05/21 05:07

  Lytix Biopharma Q1 net loss widens to NOK 25.95 million